BRPI0512677A2 - derivados de quinazolina - Google Patents

derivados de quinazolina

Info

Publication number
BRPI0512677A2
BRPI0512677A2 BRPI0512677-0A BRPI0512677A BRPI0512677A2 BR PI0512677 A2 BRPI0512677 A2 BR PI0512677A2 BR PI0512677 A BRPI0512677 A BR PI0512677A BR PI0512677 A2 BRPI0512677 A2 BR PI0512677A2
Authority
BR
Brazil
Prior art keywords
quinazoline derivatives
quinazoline
derivatives
pharmaceuticals
substituents
Prior art date
Application number
BRPI0512677-0A
Other languages
English (en)
Inventor
Hans Allgeier
Wolfgang Froestl
Manuel Koller
Henri Mattes
Joachim Nozulak
Silvio Ofner
David Orain
Vittorio Rasetti
Johanne Renaud
Nicolas Soldermann
Philipp Floersheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0512677A2 publication Critical patent/BRPI0512677A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE QUINAZOLINA. A presente invenção refere-se a derivados de 1 H-Quinazolina-2,4-diona de fórmula (1) em que os substituintes são definidos como na especificação, sua preparação, sua aplicação como farmacêuticos, e composições farmacêuticas contendo os mesmos.
BRPI0512677-0A 2004-07-27 2005-07-26 derivados de quinazolina BRPI0512677A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0416730.0A GB0416730D0 (en) 2004-07-27 2004-07-27 Organic compounds
PCT/EP2005/008113 WO2006010591A2 (en) 2004-07-27 2005-07-26 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
BRPI0512677A2 true BRPI0512677A2 (pt) 2009-01-13

Family

ID=32947511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512677-0A BRPI0512677A2 (pt) 2004-07-27 2005-07-26 derivados de quinazolina

Country Status (13)

Country Link
US (1) US8299085B2 (pt)
EP (1) EP1773788B8 (pt)
JP (1) JP4898676B2 (pt)
KR (1) KR20070044439A (pt)
CN (1) CN1989113B (pt)
AU (1) AU2005266490B2 (pt)
BR (1) BRPI0512677A2 (pt)
CA (1) CA2571223A1 (pt)
ES (1) ES2398662T3 (pt)
GB (1) GB0416730D0 (pt)
MX (1) MX2007001135A (pt)
RU (1) RU2414468C2 (pt)
WO (1) WO2006010591A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2690110A1 (en) * 2007-07-13 2009-01-22 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for neuropathic pain
PT2239257E (pt) * 2008-01-30 2012-09-12 Shin Poong Pharmaceutical Co Ltd Novo derivado de quinazolina-2,4-diona e composições médicas para a profilaxia e tratamento da doença dos nervos cranianos contendo o dito derivado
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
EP2456442A1 (en) * 2009-07-23 2012-05-30 Novartis AG 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
PH12012501289A1 (en) * 2009-12-22 2013-01-07 Novartis Ag Formulation comprising 1 h- quinazoline -2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
US20130053381A1 (en) 2010-05-20 2013-02-28 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
AU2011268865A1 (en) * 2010-06-24 2013-01-31 Novartis Ag Use of 1H-quinazoline-2,4-diones
EP2668159A1 (en) 2011-01-24 2013-12-04 Novartis AG 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
WO2020036133A1 (ja) * 2018-08-17 2020-02-20 クミアイ化学工業株式会社 ３－（１ｈ－１，２，４－トリアゾール－１－イル）安息香酸アミド誘導体及び有害生物防除剤
CN115414357B (zh) * 2022-08-30 2023-09-22 天津医科大学眼科医院 一种酰胺类化合物在制备防治近视的药物中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125485D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU4416197A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
SK113299A3 (en) * 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
TR199902094T2 (xx) 1997-02-28 1999-12-21 Prizer Products Inc. 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri.
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
JP2000309585A (ja) 1999-02-26 2000-11-07 Kyorin Pharmaceut Co Ltd ６−置換ヘテロキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
SK10572002A3 (sk) 2000-01-24 2003-10-07 Warner-Lambert Company 3-Aminochinazolín-2,4-diónové antibakteriálne činidlá
CN1335307A (zh) * 2000-07-20 2002-02-13 中国人民解放军第一军医大学 2－氨基喹唑啉酮类化合物的合成工艺
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20050037445A1 (en) 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
EP1491211A4 (en) 2002-03-29 2010-01-13 Astellas Pharma Inc DRUG AGAINST GLIOBLASTOMA
JP4175846B2 (ja) 2002-08-08 2008-11-05 独立行政法人科学技術振興機構 Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制
AU2003270446A1 (en) 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
MXPA05006798A (es) 2002-12-20 2006-03-09 Migenix Corp Ligandos de adenina nucleotido translocasa (ant) y composiciones y metodos relacionados a estos.
ATE488231T1 (de) 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
DE602004013938D1 (de) 2003-01-29 2008-07-03 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
JP4719681B2 (ja) 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリンカリウムチャネル阻害剤
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RU2414468C2 (ru) 2011-03-20
CN1989113A (zh) 2007-06-27
AU2005266490B2 (en) 2009-12-24
KR20070044439A (ko) 2007-04-27
WO2006010591A3 (en) 2006-10-12
EP1773788B1 (en) 2012-11-14
JP4898676B2 (ja) 2012-03-21
US20070208018A1 (en) 2007-09-06
EP1773788A2 (en) 2007-04-18
RU2007106930A (ru) 2008-09-10
ES2398662T3 (es) 2013-03-20
GB0416730D0 (en) 2004-09-01
EP1773788B8 (en) 2013-01-09
JP2008508216A (ja) 2008-03-21
WO2006010591A2 (en) 2006-02-02
CA2571223A1 (en) 2006-02-02
AU2005266490A1 (en) 2006-02-02
MX2007001135A (es) 2007-04-13
CN1989113B (zh) 2011-02-16
US8299085B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0512677A2 (pt) derivados de quinazolina
BR0208338A (pt) Derivados de piridina
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
UY29007A1 (es) Derivados de 2-carbamida-4-feniltiazol, su preparacinn, y su aplicacinn en terapcutica
TW200732323A (en) Organic compounds
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
BRPI0414480A (pt) derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk
TW200621729A (en) Pyrimidine derivatives
BRPI0518752A2 (pt) 1-alquinil-2-arilàxi-alquil-amidas e uso do mesmo como fungicidas
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BRPI0514731A (pt) derivados de pirimidina
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BR0314113A (pt) Derivados de amino propanol
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BR0311222A (pt) R-enantiÈmeros de derivados de piranoindol contra hepatite c, seu método de obtenção e composição farmacêutica compreendendo os mesmos
ATE449069T1 (de) Aminopropanolderivate
BR112015001207A2 (pt) derivados de carbamato/ureia
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.